AstraZeneca (MEX:AZNN) Cyclically Adjusted PB Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZNN AstraZeneca PLC MEX:AZNN
89 GF Score
Price MXN1,628.00
GF Value MXN1,841.60
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca  (MEX:AZNN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.24 9.33 8.20 7.46 8.93

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.84 7.41 8.93 9.28 8.63

MEX:AZNN vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.


MEX:AZNN
89GF Score
AstraZeneca PLC MEX:AZNN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=283.044/142.3000*142.3000
=283.044

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201609 99.903 101.500 140.061
201612 121.023 102.200 168.509
201703 96.592 102.700 133.837
201706 97.486 103.500 134.031
201709 98.380 104.300 134.223
201712 116.017 105.000 157.231
201803 92.625 105.100 125.409
201806 98.080 105.900 131.792
201809 88.122 106.600 117.634
201812 96.607 107.100 128.358
201903 77.510 107.000 103.081
201906 99.195 107.900 130.820
201909 91.526 108.400 120.149
201912 94.340 108.500 123.729
202003 96.297 108.600 126.179
202006 107.621 108.800 140.758
202009 102.644 109.200 133.757
202012 118.367 109.400 153.964
202103 112.347 109.700 145.734
202106 118.849 111.400 151.815
202109 263.765 112.400 333.930
202112 259.953 114.700 322.505
202203 233.491 116.500 285.200
202206 233.265 120.500 275.466
202209 228.047 122.300 265.340
202212 232.957 125.300 264.563
202303 208.116 126.800 233.556
202306 206.805 129.400 227.422
202309 209.023 130.100 228.624
202312 214.308 130.500 233.686
202403 200.438 131.600 216.735
202406 233.464 133.000 249.789
202409 258.586 133.500 275.631
202412 274.375 135.100 288.998
202503 270.802 136.100 283.138
202506 271.580 138.400 279.233
202509 271.496 138.900 278.142
202512 282.620 139.900 287.468
202603 275.286 140.800 278.219
202606 283.044 142.300 283.044

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AstraZeneca (MEX:AZNN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of MXN1,628.00 is trading 11.6% below its estimated GF Value™ of MXN1,841.60.

Key valuation signals for MEX:AZNN:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: MXN1,841.60 vs. price of MXN1,628.00 (11.6% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
89GF Score

Get the complete analysis for MEX:AZNN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,628.00
Price
MXN1,841.60
GF Value